Smallpox vaccine safety is dependent on T cells and not B cells
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011..
The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine. However, while depletion of both CD4(+) and CD8(+) T cells had no adverse effects on LC16m8-vaccinated animals, it caused progressive vaccinia in macaques immunized with Dryvax. As both Dryvax and LC16m8 vaccines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m8 as a safer and effective alternative to ACAM2000 and Dryvax vaccines for immunocompromised individuals.
| Errataetall: |
CommentIn: J Infect Dis. 2011 Apr 15;203(8):1037-9. - PMID 21450992 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:203 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 203(2011), 8 vom: 15. Apr., Seite 1043-53 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordon, Shari N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 10.06.2011 Date Revised 13.12.2023 published: Print CommentIn: J Infect Dis. 2011 Apr 15;203(8):1037-9. - PMID 21450992 Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiq162 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM207078742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM207078742 | ||
| 003 | DE-627 | ||
| 005 | 20231227124349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiq162 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1222.xml |
| 035 | |a (DE-627)NLM207078742 | ||
| 035 | |a (NLM)21450994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordon, Shari N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Smallpox vaccine safety is dependent on T cells and not B cells |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2011 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Infect Dis. 2011 Apr 15;203(8):1037-9. - PMID 21450992 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011. | ||
| 520 | |a The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine. However, while depletion of both CD4(+) and CD8(+) T cells had no adverse effects on LC16m8-vaccinated animals, it caused progressive vaccinia in macaques immunized with Dryvax. As both Dryvax and LC16m8 vaccines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m8 as a safer and effective alternative to ACAM2000 and Dryvax vaccines for immunocompromised individuals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Calcium-Binding Proteins |2 NLM | |
| 650 | 7 | |a Smallpox Vaccine |2 NLM | |
| 650 | 7 | |a oncomodulin |2 NLM | |
| 700 | 1 | |a Cecchinato, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Andresen, Vibeke |e verfasserin |4 aut | |
| 700 | 1 | |a Heraud, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Hryniewicz, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Parks, Robyn Washington |e verfasserin |4 aut | |
| 700 | 1 | |a Venzon, David |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Hye-kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Karpova, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a McNally, James |e verfasserin |4 aut | |
| 700 | 1 | |a Silvera, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Reimann, Keith A |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Kanehara, Tomomi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinmura, Yasuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yokote, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Franchini, Genoveffa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 203(2011), 8 vom: 15. Apr., Seite 1043-53 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:203 |g year:2011 |g number:8 |g day:15 |g month:04 |g pages:1043-53 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiq162 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 203 |j 2011 |e 8 |b 15 |c 04 |h 1043-53 | ||